Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

被引：0
|
作者：
Merryman, Reid W. [1 ]
Kline, Justin [2 ]
Redd, Robert A. [3 ]
Welsh, Emma L. [4 ]
Pfaff, Kathleen [4 ]
Lee, Hannah Juhaie [1 ]
Mcdonough, Mikaela M. [5 ]
Ahn, Inhye E. [1 ]
Brown, Jennifer R. [6 ]
Crombie, Jennifer L. [1 ]
Davids, Matthew S. [1 ]
Fisher, David C. [1 ]
Jacobsen, Eric D. [7 ]
Jacobson, Caron A. [1 ]
Kim, Austin I. [1 ,5 ]
Odejide, Oreofe O. [1 ]
Parry, Erin M. [1 ]
Ryan, Christine E. [1 ]
Shipp, Margaret A. [1 ]
Armand, Philippe [1 ]
Rodig, Scott J. [4 ]
Abramson, Jeremy S. [8 ]
Lacasce, Ann S. [1 ]
机构：
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA
[2] Univ Chicago Med, Dept Med, Sect Hematol Oncol, Chicago, IL USA
[3] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA
[4] Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[7] Dana Farber Canc Inst, Boston, MA USA
[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203414
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1669 / 1670
页数：2
相关论文
共 50 条
  • [41] PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies
    Uccella, Silvia
    Magnoli, Francesca
    Vivian, Lisa F.
    Marchiori, Deborah
    Leoni, Eleonora
    Tibiletti, Maria G.
    Sessa, Fausto
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (09) : 1293 - 1296
  • [42] PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses
    Falchi, Lorenzo
    Sawas, Ahmed
    Deng, Changchun
    Amengual, Jennifer E.
    Lichtenstein, Emily
    Khan, Karen
    Schwartz, Lawrence H.
    O'Connor, Owen A.
    BLOOD, 2016, 128 (22)
  • [43] PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies
    Volaric, Ashley
    Bacchi, Carlos E.
    Gru, Alejandro A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2020, 44 (10) : 1353 - 1366
  • [44] Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
    Pedersen, Jesper Geert
    Sokac, Mateo
    Sorensen, Boe Sandahl
    Luczak, Adam Andrzej
    Aggerholm-Pedersen, Ninna
    Birkbak, Nicolai Juul
    Ollegaard, Trine Heide
    Jakobsen, Martin Roelsgaard
    CANCERS, 2022, 14 (14)
  • [45] Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)
    Roemer, Margaretha G. M.
    Ligon, Azra H.
    Engert, Andreas
    Younes, Anas
    Santoro, Armando
    Zinzani, Pier Luigi
    Timmerman, John M.
    Ansell, Stephen
    Armand, Philippe
    Fanale, Michelle A.
    Ratanatharathorn, Voravit
    Kuruvilla, John
    Cohen, Jonathon B.
    Collins, Graham P.
    Savage, Kerry J.
    Trneny, Marek
    Neuberg, Donna S.
    Redd, Robert A.
    Farsaci, Benedetto
    Kato, Kazunobu
    Sumbul, Anne
    Rodig, Scott J.
    Shipp, Margaret A.
    BLOOD, 2016, 128 (22)
  • [46] PD-1 blockade prevents the progression of oral carcinogenesis
    Dong, Yunmei
    Wang, Zhen
    Mao, Fei
    Cai, Luyao
    Dan, Hongxia
    Jiang, Lu
    Zeng, Xin
    Li, Taiwen
    Zhou, Yu
    Chen, Qianming
    CARCINOGENESIS, 2021, 42 (06) : 891 - 902
  • [47] Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
    Zimmer, Lisa
    Apuri, Susmitha
    Eroglu, Zeynep
    Kottschade, Lisa A.
    Forschner, Andrea
    Gutzmer, Ralf
    Schlaak, Max
    Heinzerling, Lucie
    Krackhardt, Angela M.
    Loquai, Carmen
    Markovic, Svetomir N.
    Joseph, Richard W.
    Markey, Kelly
    Utikal, Jochen S.
    Weishaupt, Carsten
    Goldinger, Simone M.
    Sondak, Vernon K.
    Zager, Jonathan S.
    Schadendorf, Dirk
    Khushalani, Nikhil I.
    EUROPEAN JOURNAL OF CANCER, 2017, 75 : 47 - 55
  • [48] Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
    Fedorova, Liudmila, V
    Lepik, Kirill, V
    Volkov, Nikita P.
    Kotselyabina, Polina, V
    Borzenkova, Evgenia S.
    Popova, Marina O.
    Beynarovich, Anastasia, V
    Baykov, Vadim V.
    Kozlov, Andrey, V
    Moiseev, Ivan S.
    Mikhailova, Natalia B.
    Kulagin, Alexander D.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (03) : 626 - 632
  • [49] Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
    Liudmila V. Fedorova
    Kirill V. Lepik
    Nikita P. Volkov
    Polina V. Kotselyabina
    Evgenia S. Borzenkova
    Marina O. Popova
    Anastasia V. Beynarovich
    Vadim V. Baykov
    Andrey V. Kozlov
    Ivan S. Moiseev
    Natalia B. Mikhailova
    Alexander D. Kulagin
    International Journal of Clinical Oncology, 2022, 27 : 626 - 632
  • [50] Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
    Villasboas, Jose Caetano
    Ansell, Stephen M.
    Witzig, Thomas E.
    ONCOTARGET, 2016, 7 (11) : 13260 - 13264
12345